Anti-H3L Antibody (NAL_A185) 

Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease^[1][2][3].

Affinity-purified human Anti-H3L Antibody (44 μg/mL; 16-18 h virus-antibody incubation, 2 days total assay) potently neutralizes vaccinia virus strain WR in CV-1 cells with a PRNT₅₀ of 44 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-H3L Antibody (50 μg; i.p.; four times at 2-week intervals; single final booster dose) is yielded from immunization of BALB/c mice with MBP-H3L that induces a strong specific antibody response, cross-reacts with MPXV and VACV H3L and mediates complement-dependent neutralization of MPXV^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

[Anti-H3L Antibody (NAL_A185)]

Room temperature in continental US; may vary elsewhere.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Davies DH, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005;79(18):11724-11733.  [Content Brief]

  [2]. Huang IH, et al. Monkeypox virus H3L protein as the target antigen for developing neutralizing antibody and serological assay. Appl Microbiol Biotechnol. 2025;109(1):80. Published 2025 Apr 2.  [Content Brief]

  [3]. Yefet R, et al. Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. iScience. 2023;26(2):105957.  [Content Brief]